WO2007005672A3 - Treatment and prevention of respiratory diseases and conditions - Google Patents

Treatment and prevention of respiratory diseases and conditions Download PDF

Info

Publication number
WO2007005672A3
WO2007005672A3 PCT/US2006/025705 US2006025705W WO2007005672A3 WO 2007005672 A3 WO2007005672 A3 WO 2007005672A3 US 2006025705 W US2006025705 W US 2006025705W WO 2007005672 A3 WO2007005672 A3 WO 2007005672A3
Authority
WO
WIPO (PCT)
Prior art keywords
conditions
respiratory diseases
prevention
treatment
methods
Prior art date
Application number
PCT/US2006/025705
Other languages
French (fr)
Other versions
WO2007005672A2 (en
Inventor
Charles G Chochrane
Original Assignee
Scripps Research Inst
Charles G Chochrane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, Charles G Chochrane filed Critical Scripps Research Inst
Publication of WO2007005672A2 publication Critical patent/WO2007005672A2/en
Publication of WO2007005672A3 publication Critical patent/WO2007005672A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395Alveolar surfactant peptides; Pulmonary surfactant peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides compositions and methods for treating respiratory diseases and conditions. Such compositions and methods utilize a neutral lipid and a phospholipid combined with a lung surfactant polypeptide.
PCT/US2006/025705 2005-06-30 2006-06-30 Treatment and prevention of respiratory diseases and conditions WO2007005672A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69583005P 2005-06-30 2005-06-30
US60/695,830 2005-06-30

Publications (2)

Publication Number Publication Date
WO2007005672A2 WO2007005672A2 (en) 2007-01-11
WO2007005672A3 true WO2007005672A3 (en) 2007-05-10

Family

ID=37521580

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/025705 WO2007005672A2 (en) 2005-06-30 2006-06-30 Treatment and prevention of respiratory diseases and conditions

Country Status (1)

Country Link
WO (1) WO2007005672A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2562806T3 (en) * 2007-06-05 2016-03-08 Paka Pulmonary Pharmaceuticals, Inc. Compositions for administering medications in the lungs, and uses thereof
AU2009324637B2 (en) 2008-12-10 2016-09-08 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of medicaments to the lungs
WO2010087771A1 (en) * 2009-01-30 2010-08-05 Alphabeta Ab Compound and method for treatment of alzheimer's disease
AU2010356144B2 (en) 2010-06-24 2015-06-04 Alphabeta Ab Compound and method for treatment of Alzheimer's disease and familial dementia
US9522170B2 (en) 2011-04-05 2016-12-20 Alphabeta Ab Methods of screening compounds for the fibril formation of Aβ peptides based on a decreased trimer/monomer ratio of a chaperone protein
WO2013188016A2 (en) * 2012-05-04 2013-12-19 Discovery Laboratories, Inc. Surfactant therapy for exposure to ionizing radiation
US20160235813A1 (en) * 2013-09-18 2016-08-18 James Cook University Anti-inflammatory proteins and methods of use
AU2014324094B2 (en) 2013-09-18 2019-03-14 James Cook University Modified anti-inflammatory proteins and method of use
CN104382942A (en) * 2014-11-05 2015-03-04 烟台东诚药业集团股份有限公司 Novel process for preparing swine pulmonary surfactant suspension
MX2020011127A (en) * 2018-04-23 2021-01-15 Chiesi Farm Spa A therapeutic combination comprising a pulmonary surfactant and a steroid for the prophylaxis of bpd.
CN115414473A (en) * 2022-08-25 2022-12-02 中国人民解放军军事科学院军事医学研究院 Collagenase liposome inhalant and application thereof in treating pulmonary fibrosis

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0406998A2 (en) * 1989-03-15 1991-01-09 Board Of Regents, The University Of Texas System Use of phospholipids in lung surfactant replacement therapy
US5260284A (en) * 1987-02-17 1993-11-09 Board Of Regents, The University Of Texas System Methods employing unique mixtures of polar and neutral lipids and sterol for lung surfactant replacement therapy
US20020099033A1 (en) * 1997-04-16 2002-07-25 Wisconsin Alumni Research Foundation Method and composition for treating sleep apnea
WO2003035679A2 (en) * 2001-10-25 2003-05-01 Medical Research Council Molecules
WO2003090682A2 (en) * 2002-04-25 2003-11-06 The Scripps Research Institute Treatment and prevention of pulmonary conditions
WO2005055994A1 (en) * 2003-12-04 2005-06-23 The Scripps Research Institute Treatment and preventions of asthma

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260284A (en) * 1987-02-17 1993-11-09 Board Of Regents, The University Of Texas System Methods employing unique mixtures of polar and neutral lipids and sterol for lung surfactant replacement therapy
EP0406998A2 (en) * 1989-03-15 1991-01-09 Board Of Regents, The University Of Texas System Use of phospholipids in lung surfactant replacement therapy
US20020099033A1 (en) * 1997-04-16 2002-07-25 Wisconsin Alumni Research Foundation Method and composition for treating sleep apnea
WO2003035679A2 (en) * 2001-10-25 2003-05-01 Medical Research Council Molecules
WO2003090682A2 (en) * 2002-04-25 2003-11-06 The Scripps Research Institute Treatment and prevention of pulmonary conditions
WO2005055994A1 (en) * 2003-12-04 2005-06-23 The Scripps Research Institute Treatment and preventions of asthma

Also Published As

Publication number Publication date
WO2007005672A2 (en) 2007-01-11

Similar Documents

Publication Publication Date Title
WO2007005672A3 (en) Treatment and prevention of respiratory diseases and conditions
WO2006119329A3 (en) Compositions and methods for the treatment of neurodegenerative diseases
WO2007101551A3 (en) Phospholipid complexes of curcumin having improved bioavailability
WO2006045096A3 (en) Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
WO2006024018A3 (en) Compositions for treating nociceptive pain
WO2006091459A3 (en) Compositions and methods for treating vascular permeability
WO2005085266A8 (en) Macrocyclic compounds and methods of making and using the same
WO2006020040A3 (en) Apolipoprotein a1 mimetics and uses thereof
WO2007008529A3 (en) Celullar cholesterol absorption modifiers
WO2005105113A3 (en) Therapeutic compositions containing at least one pyrrolobenzodiazepine derivative and fludarabine
WO2006127757A3 (en) Interferon-igg fusion
PL1799231T3 (en) Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases
WO2007127841A3 (en) Compositions and methods of preparation thereof
WO2008049000A3 (en) Combination therapy for pulmonary arterial hypertension
WO2008002591A3 (en) Methods for treating atherosclerosis
WO2007092622A3 (en) Compositions and methods for treating bone
WO2007095288A3 (en) Methionine-containing protein or peptide compositions and methods of making and using
WO2005118511A3 (en) Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
WO2008081934A1 (en) Agent for facilitating the development of brain in infant comprising milk-derived phospholipid and food composition comprising the same
MY147247A (en) Organic compounds and their uses
WO2008143633A3 (en) Compounds and methods for treatment of alpha-1 antitrypsin deficiency
WO2007109037A3 (en) Thiazolidinedione analogues for the treatment of hypertension and for lowering lipids
WO2009015314A3 (en) Modified lecithin-cholesterol acyltransferase enzymes
WO2006128041A3 (en) Compositions and methods for the treatment or prevention of chemoresistant neoplasia
WO2006091542A3 (en) Use of sildenafil, vardenafil and other 5-phosphodiesterase inhibitors to enhance permeability of the abnormal blood-brain barrier

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06786042

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06786042

Country of ref document: EP

Kind code of ref document: A2